Breast Cancer Prevention & Early Detection

If we can create a human cell atlas based on genetic ancestry, that would help in streamlining disease characterization and addressing health disparities among different ethnic populations.

Hari Nakshatri, PhD — Marian J. Morrison Professor of Breast Cancer Research

Reducing the density of breast tissue

Endoxifen is a purified Tamoxifen metabolite developed as an alternative drug and now used by women who are unable to take Tamoxifen to suppress estrogen production.

The metabolite, discovered in the early 2000s by Todd Skaar, PhD, and his mentor, the late David Flockhart, MD, is more potent than Tamoxifen, allowing for smaller doses to be taken.

Now, Swedish pharmaceutical company Atossa Therapeutics is recruiting patients in a Phase II clinical trial studying the use of Skaar’s metabolite in reducing breast density.

Phase I Clinical Trial Phase II Clinical Trial

About the Vera Bradley Foundation Center for Breast Cancer

To date, the Vera Bradley Foundation, a 501(c)(3) non-profit fundraising organization, has committed more than $50 million to advance breast cancer research and treatment in Indiana and around the world.

Website Facebook


Support Our Research